Jpmorgan Chase & CO Vyne Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.12 - $4.91 $1 - $49	-10 Reduced 5.52%	171 $0
Q3 2022 Nov 14, 2022	BUY	$0.24 - $4.27 $2 - $42	10 Added 5.85%	181 $0
Q2 2022 Aug 11, 2022	SELL	$0.37 - $0.71 $1,883 - $3,614	-5,091 Reduced 96.75%	171 $0
Q1 2022 May 11, 2022	BUY	$0.5 - $1.15 $2,546 - $5,856	5,093 Added 3013.61%	5,262 $3,000
Q4 2021 Feb 10, 2022	SELL	$0.91 - $1.5 $3,289 - $5,422	-3,615 Reduced 95.53%	169 $0
Q3 2021 Nov 12, 2021	BUY	$1.39 - $3.47 $5,259 - $13,130	3,784 New	3,784 $5,000

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $176M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.